In addition to consolidations at its New Jersey R&D facility, Roche (RHHBY.PK +1.9%) says...


In addition to consolidations at its New Jersey R&D facility, Roche (RHHBY.PK +1.9%) says Jean-Jacques Garaud, its head of Pharmaceutical Research and Early Development, is leaving the company effective June 30. Mike Burgess, currently Global Head Oncology and Large Molecule Research, will become acting head until a replacement its found, reporting directly to CEO Severin Schwan.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs